drugset
drugset / Trial / NCT02215759

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

NCT02215759 ↗

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of safety, tolerability and pharmacokinetics of multiple rising oral doses of BI 44370 TA in healthy male and female volunteers

Timeline

Start
2009-01
Primary completion
2009-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule 100 mg Oral
Subject BI 44370 Small molecule 200 mg Oral
Subject BI 44370 Small molecule 300 mg Oral

Indications

No indication recorded.